About Us

Bringing actionable intelligence and strategic insight to make better and informed decision

OncoCI is part of CompEdge group and focus solely on Oncology/ImmunoOncology therapeutic area. We support our partner’s strategic intelligence needs emerging at different stages of the drug development- right from the preclinical to clinical stage assessment. OncoCI provides precisely relevant strategic support and impactful insight to global pharma innovators and biotech companies of all sizes, including emerging start-ups, mid or big sized pharma companies, and academic collaborators. Our team comprises of 50+ top expert consultants, R&D scientists, Data Analysts and subject matter experts curated from the top ranked global innovator companies and academic institutions worldwide. OncoCI team has global footprint and present in the USA (Boston and Delaware) and India (Delhi and Hyderabad), that bring together a world-class network of professionals serving best in Oncology Consulting and Competitive Intelligence Industry .

Our Founders

team
Dr. Ana Maria Waaga-Gasser, (Ph.D.)

Faculty, Harvard Medical School

A dynamic and broadly experienced leader with expertise...

Read More
team
Dr Thomas Boldicke, (Ph.D.)

Faculty, Helmholtz Centre for Infection Research

Thomas Boldicke is senior scientist at the Helmholtz ...

Read More
team
Dr Amrendra K. Ajay, (Ph.D.)

Faculty, Harvard Medical School

Dr Ajay has 15+ years of expertise in oncology, tumor profiling with special...

Read More
team
Dr Vimal Pandey, (Ph.D.)

Oncology Consultant

Dr Vimal Pandey has over 15 years of work experience in strategic assessments, CI monitoring and...

Read More

Offerings

Designing solutions for your most difficult business challenges and building winning strategies together.


Competitive
Intelligence
  • Preclinical Development
  • Clinical Development
Strategy Consulting
and Insight
  • We partner with clients and deliver the highest quality of actionable intelligence and strategic insight.
Conference
Coverage
  • We make easier for you to follow all key Oncology conferences. Our team can quicky build a consolidated report with added insights for you based on your specific need.
KOL
Identification
  • Keeping your company’s goals in mind, we will support you in identifying and connecting with the right sets of area experts who can help you on the path to success.
stats

Preclinical OncoCI Support

Understand the data and know the potential competitors much before their clinical entry- Don’t skip this critical step

Key Business Challenges

  • Critical analysis of preclinical data
    • Activity (tumor growth regression, growth inhibition, survival)
    • Safety (toxicities, deaths and weight loss)
    • PK/PD correlation of animal studies
    • Designing optimal mechanistic studies and animal models
    • Optimizing dosing frequency and schedule
    • Biomarker correlation with activity
    • Many more…
  • Benchmarking preclinical data for clinical success
  • Clinical translatability assessment of preclinical studies
  • Optimal trial design based on the preclinical evidences
  • Key learning out of a failed study: Improve your likelihood of clinical success

Clinical OncoCI Support

We offer customized CI reports based on the clinical developmental landscape and support our clients in making well-informed decisions to prioritize the disease, asset, portfolio, and investment.

  • Tracking clinical development (Specific MoA/Tumor) –
    Comprehensive coverage of trial design, intervention regimens, phases, recruitment status, trial start and completion dates, locations, sponsors/collaborators, drug MoAs, route of administration, primary endpoints, combination therapy strategies, efficacy and adverse events readouts, patients inclusion criteria , biomarkers, any other specific patient segment
  • Identification and prioritization of drug targets/ tumors/ MoAs/drug combinations/ patient segments for early or late stage drug development
  • Disease and target opportunity profiles (DOPs/TOPs/TPPs)
  • Drug MoAs and tumor specific reports
  • Efficacy data benchmarking
  • Tumor specific treatment algorithm (standard of care)
  • Tracking of Pivotal Trials , Registrational Trials, Special designations, Failed Trials, ODAC committee and Approvals (FDA, China, Europe, Japan and ROW)
  • Time to market estimation
  • Competitor profiling and monitoring
  • CI monitoring support
stats
stats

Strategy Consulting and Insight

Designing strategies together to support your product’s success

  • Disease prioritization: where to play/how to win in near or long term horizons
  • Assets strategy: go/no-go decision, LCM strategy
  • Opportunity assessment (Disease/ Drug- Monotherapy/Combination)
  • Competitor portfolio mapping
  • Scientific and commercial assessment
  • Situational assessment
  • MoA/Tumor report
  • Whitespace analysis
  • Forward looking strategy
  • Any other, as per your strategic need

KOL Identification

Keeping your company’s goals in mind, OncoCI will support you in identifying and connecting with the right sets of area experts who can help you on the path to clinical success. We have a comprehensive network of key opinion leaders (KOLs) who can share unparalleled insights regarding the drug development process, regulatory drug development requirements, developing efficient marketing strategies and also guide in identifying unmet needs and gaps in the market to capitalize on ideal opportunities.

stats

Conference Coverage

Customized conference summaries with an additional layer of insights, which is provided in the expert analysis that comes with the report.

  • ASCO Gastrointestinal (GI) Cancers Symposium (January)
    It offers the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care
  • ASCO Genitourinary (GU) Cancers Symposium (February)
    The GU Cancers Symposium is designed to provide attendees with an in-depth, multidisciplinary analysis of the most timely topics in the diagnosis, treatment, and study of GU malignancies
  • American Association for Cancer Research (AACR) Annual Meeting (April)
    The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine
  • The American Society of Clinical Oncology (ASCO) Annual Meeting (June)
    ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer
  • European Hematology Association (EHA) Congress (June)
    EHA presents the latest news in hematology and its subspecialties with evidence-based approaches to diagnosis and treatment, recent clinical and translational research data, and more
  • World Conference on Lung Cancer (WCLC) (August/September)
    World's largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology
  • European Society for Medical Oncology (ESMO) Congress (September)
    ESMO is the leading professional organization for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information
  • Society for Immunotherapy of Cancer (SITC) Annual Meeting (November)
    SITC provides a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy
  • The American Society of Hematology (ASH) Annual Meeting (December)
    ASH is the world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases
  • The San Antonio Breast Cancer Symposium (SABCS) (December)
    The symposium’s mission has been to provide state-of-the-art information on breast cancer research

MoAs/Modalities Coverage Across the Tumors

Our Locations

Registered office
DELWARE: 16192 Coastal Highway Lewes, Delaware County of Sussex USA 19958

Offices
BOSTON (HQ): 84 Park Ave Ext Arlington, MA USA 02474

DELHI-NCR: Plot – 27, Galaxy Business Park, Sector-62, Noida

HYDERABAD: KV Rangareddy-19, Telangana, 500019 India

Mail us:
Please reach out to us on your specific queries:
Explore our offerings: bd@oncoci.com, akajay@oncoci.com
For any other information: info@oncoci.com

Contact Us